Related by context. All words. (Click for frequent words.) 77 HCV genotypes 74 CCR5 tropic HIV 73 HCV genotype 1 72 hepatitis C genotype 72 chronic HCV genotype 70 treatment naive genotype 69 seronegative 68 virologic failure 68 treatment naïve genotype 68 HCV SPRINT 68 genotype 68 PEG IFN 67 HBeAg positive 67 virological response 66 stage IIIB 66 seropositivity 66 HBeAg negative 66 mg/m2 dose 66 severe neutropenia 65 mg kg dose 65 genotypic resistance 65 chronic HCV infection 65 ribavirin RBV 65 grade cervical intraepithelial 65 coinfected 65 leukemia AML 65 NNRTI resistance 65 genotype 1b 65 seroprotection 65 Peg IFN 65 seroconversion 65 gemcitabine carboplatin 65 log# copies mL 64 genotype 1a 64 mCRC patients 64 CR nPR 64 log# reduction 64 PegIFN RBV 64 KRAS wild 64 mcg BID 64 lymphocytosis 64 virologic response 64 NRTI resistance 64 ribavirin therapy 64 HCV infected 64 relapsed MM 64 null responders 64 pegylated interferon alfa 2a 64 peginterferon alfa 2b 64 evaluable patients 64 alfa 2a 64 sustained virological response 64 metastatic RCC 64 virologic responses 64 interferon alfa 2b 64 sustained virologic response 64 HBsAg 64 unresectable stage 64 null responder 64 K ras mutations 64 chronic HBV 64 histologically confirmed 64 viremia 64 #mg QD [002] 63 mcg albinterferon alfa 2b 63 KRAS mutations 63 biochemical relapse 63 chlorambucil 63 antibody titer 63 antiretroviral naive 63 ceftazidime 63 HIV RNA 63 recurrent glioblastoma multiforme 63 viral kinetics 63 mRCC 63 #mg BID [001] 63 ECOG PS 63 chronic HCV 63 heavily pretreated 63 ALT elevation 63 metastatic malignant melanoma 63 gastric adenocarcinoma 63 BARACLUDE ® 63 lamivudine refractory patients 63 locoregional recurrence 63 LTBI 63 HBeAg seroconversion 63 hepatitis C HCV 63 HTLV 63 low dose cytarabine 63 Peginterferon Alfa 2a 63 virological failure 63 CC genotype 63 KRAS status 63 rapid virologic response 63 antiretroviral naïve 63 μmol L 63 HCV RESPOND 2 63 PREZISTA r 62 piperacillin tazobactam 62 CIN2 62 Partial Responses 62 naïve HCV 62 metastatic renal cell carcinoma 62 IFN α 62 UGT#A# * 62 abacavir lamivudine 62 GISTs 62 T2DM 62 tigecycline 62 XELOX 62 dosage regimens 62 mildly symptomatic 62 myelodysplastic syndromes MDS 62 basal cell carcinoma BCC 62 % CI #.#-#.# [007] 62 EGFR mutations 62 K#N 62 peginterferon alfa 62 pegIFN 62 HIV uninfected 62 fallopian tube carcinoma 62 HBeAg 62 inhibitor RG# 62 progression TTP 62 ertapenem 62 hepatocellular cancer 62 telaprevir dosed 62 Chronic Hepatitis C 62 HPV-#/# 62 IU ml 62 TIMP 62 FOLFIRI 62 mcg mL 62 Pegylated interferon 62 IV NSCLC 62 TMC# C# 62 undetectable HCV RNA 62 q#h 62 Genotype 62 ALT flares 62 evaluable 62 Copegus ribavirin 62 dacarbazine 62 leukocyte count 62 SVR# 62 LEXIVA r 62 #mg BID [003] 62 adriamycin 61 micafungin 61 chronic HBV infection 61 homozygotes 61 NRTI backbone 61 VFEND 61 HBeAg positive patients 61 virologic suppression 61 dosing cohorts 61 Randomized Phase 61 Flu Cy 61 FOLFOX 61 FOLFIRI alone 61 lopinavir r 61 histologies 61 plus dexamethasone 61 EGFR mutation positive 61 VELCADE melphalan 61 Pharmacokinetics PK 61 interferon ribavirin 61 pegylated interferon alpha 61 del 5q 61 ovarian carcinoma 61 HIV coinfected 61 trabectedin 61 evaluable subjects 61 GOUT 61 q8h 61 anemia hemoglobin 61 ritonavir boosted 61 adjunctive placebo 61 mcg dose 61 RECIST criteria 61 tenofovir emtricitabine 61 coinfection 61 liver transplant recipients 61 resectable 61 leukemia CLL 61 Peginterferon 61 naive HCV genotype 61 refractory CLL 61 achieved sustained virological 61 HCV Genotype 61 coinfected patients 61 HER2 expression 61 seropositive patients 61 TMC# r 61 Pegasys plus Copegus 61 HCV infection 61 ASCUS 61 rizatriptan 61 peginterferon 61 peginterferon alfa 2a 61 follicular lymphomas 61 hepatocellular carcinomas 61 hematologic toxicity 61 4mg/kg 61 pheochromocytoma 61 PegIFN 61 invasive candidiasis 61 Doxil ® 61 candidemia 61 seropositive 61 PCa 61 ritonavir boosted atazanavir 61 REYATAZ r arm 61 dasatinib Sprycel ® 61 adjuvant trastuzumab 61 5-FU/LV 61 mutated KRAS 61 fluvastatin 61 papillary renal cell carcinoma 61 pancreatic adenocarcinoma 61 completely resected 61 TRAIL R1 60 daunorubicin 60 seroconverted 60 KRAS mutations occur 60 dacarbazine DTIC 60 clade B 60 pegylated interferon alfa 60 CLL SLL 60 neutropenia dehydration dyspnea 60 nitazoxanide 60 aminotransferase levels 60 anti HBs 60 HGS ETR2 60 FLT3 60 HER2 negative 60 pegylated liposomal doxorubicin 60 CMV infection 60 heterozygotes 60 antiviral efficacy 60 biochemical recurrence 60 antibody titers 60 adalimumab 60 interferon alfa 2a 60 μg dose 60 NNRTI resistant virus 60 HIV HCV coinfected 60 transaminase elevations 60 CIN3 60 APTIVUS r 60 HBeAg negative chronic hepatitis 60 bendamustine 60 carboplatin paclitaxel 60 pT3 60 PREZISTA ritonavir 60 neoadjuvant 60 imatinib Gleevec ® 60 HBeAg negative patients 60 mg ustekinumab 60 interferon alfa 60 K#R [002] 60 epithelial ovarian 60 Aptivus ® 60 Viramidine 60 comparator arm 60 HPV subtypes 60 peginterferon alpha 2a 60 Elitek 60 e antigen HBeAg 60 HCV 60 LUX Lung 60 PRECiSE 60 Aflibercept 60 pT2 60 Bezielle 60 undetectable HBV DNA 60 liver metastases 60 nonmetastatic 60 tumor xenograft models 60 mg Proellex 60 % CI #.#-#.# [003] 60 adjunctive ABILIFY 60 baseline HbA1c 60 ABC/3TC 60 neutropenic fever 60 tumor histology 60 immunocompetent 60 dose cohort 60 imatinib therapy 60 lopinavir r arm 60 rilpivirine 60 DAS# remission 60 recurrent NSCLC 60 tipranavir ritonavir 60 neutrophil counts 60 certolizumab 60 superinfection 60 CMV disease 60 EGFR TKI 60 ancrod 60 ADPKD 60 R# #mg BID 60 lamivudine 60 saline placebo 60 fluoropyrimidine 60 achieve sustained virologic 60 resected pancreatic cancer 60 taxane resistant 60 underwent resection 60 hypercholesterolemic patients 60 NY ESO 60 recurrent genital herpes 60 CCR5 tropic 60 autoantibody positive 60 cilengitide 60 abacavir Ziagen 60 Pegylated Interferon 60 refractory AML 60 pomalidomide 60 fluorouracil leucovorin 60 nelfinavir 60 Wistar rats 60 receiving VICTRELIS 60 CIN2 + 60 poor metabolizers 60 Immunohistochemical analysis 60 ErbB2 positive 60 definite stent thrombosis 60 receptor blocker 60 complete cytogenetic response 60 HBeAg + 59 BCG vaccinated 59 histologically 59 LPV r 59 NRTI 59 cisplatin vinorelbine 59 IV melanoma 59 C. trachomatis 59 docetaxel chemotherapy 59 mg BID 59 demonstrated antitumor activity 59 HER2 positive metastatic breast 59 recurrent VTE 59 8mg/kg 59 HBV genotype 59 highly immunogenic 59 HER2 amplification 59 adefovir 59 CCyR 59 thromboembolic complications 59 celgosivir 59 hepatocellular carcinoma HCC 59 G#DT 59 adjuvant tamoxifen 59 5-fluorouracil/leucovorin 59 virologic 59 cEVR 59 Pemetrexed 59 metastatic neuroendocrine tumors 59 colorectal carcinoma 59 pCR 59 rhIGFBP 3 59 clodronate 59 TEAEs 59 T#I [002] 59 Initiate Phase 59 BRAF V#E mutation 59 metastatic GIST 59 elevated LDH 59 MYCN amplification 59 valopicitabine 59 oral allopurinol 59 receptor tyrosine kinase inhibitor 59 plasma uric acid 59 timepoints 59 epithelial ovarian cancer 59 cervical intraepithelial neoplasia 59 null responder HCV 59 FOLFOX4 59 n = 59 IGFBP 59 heterozygous 59 darunavir ritonavir 59 methotrexate monotherapy 59 HGPIN 59 achieved sustained virologic 59 ara C 59 DEB# 59 titers 59 Naive Patients 59 microg 59 CYP#C# * 59 genotypes 59 recurrent glioblastoma 59 liver histology 59 macroalbuminuria 59 FOLPI 59 TMC# [002] 59 protease inhibitor PI 59 plus ribavirin 59 systemic ALCL 59 oral FTY# 59 ascending doses 59 microbiological eradication 59 platinum refractory 59 laboratory abnormalities 59 3TC lamivudine Epivir 59 achieve sustained virological 59 pegylated alpha interferon 59 glycated hemoglobin levels 59 alpha 2b 59 TDF FTC 59 highly emetogenic 59 CR CRu 59 elevated triglyceride levels 59 nucleotide analogs 59 idiopathic PAH 59 HLA DR 59 BRIM3 59 NMIBC 59 Gleevec resistant 59 XIENCE V PROMUS Stent 59 TMC# [001] 59 mycophenolate mofetil 59 trimethoprim sulfamethoxazole 59 advanced adenoma 59 abnormal cytology 59 erlotinib Tarceva ® 59 RRMS patients 59 NNRTIs 59 platelet inhibitor 59 peripheral blood mononuclear 59 PROSTVAC VF 59 histologic subtype 59 locoregional disease 59 Telintra 59 ug mL 59 replicon 59 R5 tropic 59 sorafenib Nexavar 59 prostate cancer CRPC 59 lamivudine monotherapy 59 virus HBV 59 5FU 59 vicriviroc 59 Median PFS 59 unresectable 59 euthyroid 59 Stage IIIb 59 cancer mCRC 59 mucinous 59 elevated ALT 59 metastatic gastric 59 IgM 59 ug dose 59 Acute Myeloid Leukaemia AML 59 plus COPEGUS 59 low expressors 59 invasive aspergillosis 59 myeloproliferative diseases 59 prospectively defined 59 efavirenz EFV 59 % Confidence Interval 59 taxane chemotherapy 59 ALT elevations 59 baseline FEV 59 CrCl 59 Virulizin ® 59 bexarotene 59 pegylated IFN 59 CTAP# Capsules 59 μg ml 59 malignant lymphoma 59 Pegylated Liposomal Doxorubicin 59 trastuzumab Herceptin R 59 advanced hepatocellular carcinoma 59 EGFR mutation 59 Multiple Myeloma MM 58 breast carcinoma 58 lymphadenopathy 58 naive HCV 58 prior chemotherapy regimens 58 expressors 58 undetectable virus HCV 58 Pivotal Phase 58 rituximab refractory 58 ACTEMRA TM 58 alpha2 58 intramuscularly 58 MAGE A3 ASCI 58 plasma pharmacokinetics 58 external genital lesions 58 galiximab 58 IgA deficiency 58 rapid virological response 58 gemcitabine Gemzar 58 dapagliflozin plus 58 Adjuvant chemotherapy 58 pg ml 58 herpesviruses 58 median PFS 58 SGPT 58 HBV infection 58 sorafenib Nexavar ® 58 posaconazole 58 gefitinib 58 mg TID 58 generation NNRTI 58 generalized edema 58 HBV DNA 58 nonsmall cell lung cancer 58 Squamous 58 histological subtype 58 imatinib resistant 58 radiotherapy RT 58 solithromycin 58 neoadjuvant chemotherapy 58 placebo controlled Phase 58 PC DAC Exendin 58 receptor inhibitor 58 Median survival 58 free survival PFS 58 colorectal liver metastases 58 LymphoStat B belimumab 58 anti EGFR antibody 58 peg IFN 58 antitumor effect 58 caspofungin 58 decitabine 58 biologic DMARD 58 dopamine partial agonist 58 castration resistant prostate cancer 58 serum concentrations 58 CYP#D# genotype 58 Lymphocytic 58 PEG Interferon alfa 58 HNSCC 58 PREZISTA rtv 58 tumor recurrence 58 teriflunomide 58 administered subcutaneously 58 anti leukemic 58 syngeneic 58 MPS IVA 58 operable breast cancer 58 HER2 positive cancers 58 leukopenia 58 essential thrombocythemia 58 fallopian tube cancers 58 LRAT 58 relapsed refractory multiple myeloma 58 TOP2A 58 Natalizumab 58 oral ridaforolimus 58 CYT# potent vascular disrupting 58 invasive ductal 58 locoregional 58 mapatumumab 58 M#V mutation 58 confidence interval #.#-#.# 58 dose cohorts 58 dosing cohort 58 5alpha reductase 58 recurrent glioma 58 INCB# [003] 58 breast carcinomas 58 FOLFOX6 58 undetectable viral load 58 liposomal amphotericin B 58 herpes simplex virus 58 sodium glucose cotransporter 58 KRAS mutation 58 adefovir treated 58 x ULN 58 neutralizing antibody 58 invasive carcinomas 58 PSA nadir 58 Dr. McHutchison 58 stage IIIb IV 58 novel VDA molecule 58 atazanavir ritonavir 58 FluCAM arm 58 nilotinib 58 refractory multiple myeloma 58 chronic lymphocytic leukemia CLL 58 rs# [001] 58 neutropaenia 58 thymoma 58 Sustained Virologic Response 58 anaplastic astrocytomas 58 indinavir 58 HCV replicon 58 de novo AML 58 pyrexia mucositis sepsis febrile 58 Engerix B 58 pancreatic neuroendocrine tumors 58 Janus kinase 58 lymphoid malignancies 58 stage IIIA 58 docetaxel Taxotere ® 58 prostate carcinoma 58 alpha 2a 58 aHUS 58 TroVax ® 58 #mg/m# [001] 58 ORENCIA ® 58 tocilizumab 58 C#BL 6 mice 58 peritoneal cancer 58 #mg QD [001] 58 small lymphocytic lymphoma 58 imipenem 58 MADRS score 58 Soft Tissue Sarcoma 58 serum IGF 58 virus HCV infection 58 hormone refractory 58 hA# 58 SCCHN 58 HSCT 58 posttreatment 58 nucleotide analog 58 varicella zoster virus VZV 58 CIMZIA TM 58 alanine aminotransferase ALT 58 Parathyroid Hormone 58 recurrent malignant glioma 58 serum HBV DNA 58 voriconazole 58 patients evaluable 58 plus methotrexate 58 Ophena TM 58 BCG refractory 58 colesevelam HCl 58 seliciclib 58 immunomodulatory therapy 58 bladder carcinoma 58 del 5q MDS 58 heavily pretreated patients 58 mg QD 58 interferon α 58 pegylated interferon 58 VAX# 58 EGFR HER2 58 enfuvirtide 58 virologically 58 YERVOY 58 stage IIIB IV 58 diabetes mellitus DM 58 APOPTONE 58 endometrial hyperplasia 58 DMARD 58 serum HCV RNA 58 interleukin IL 58 plasma HCV RNA 58 nonresponders 58 EURIDIS 58 P aeruginosa 58 PEGINTRON TM 58 leukemia ALL 58 HPV# 58 phase IIb study 58 PCNSL 58 SCIg 58 DENV 58 non splenectomized 58 Solid Tumors criteria 58 HLA DR2 58 tipranavir r 58 Leukemias 58 antibody responses 58 TNF antagonist 58 IL#B 58 intact parathyroid hormone 58 Virologic 58 lamivudine resistant 58 APTIVUS R 58 androgen deprivation 58 oral diclofenac 58 elacytarabine 58 xenograft models 58 Solid Tumors 58 gastrointestinal stromal tumor GIST 58 BRCA1 mutation carriers 57 serum antibody 57 prostate cancer PCa 57 pegylated interferon alfa 2b 57 NSCLC 57 Genotypes 57 VP# [004] 57 mutated K ras 57 dyslipidaemia 57 virus HCV 57 % CI #.#-#.# [006] 57 5HT 57 PAOD 57 febrile neutropenia 57 chronic hepatitis cirrhosis 57 colon carcinoma 57 TACI mutations 57 p = NS 57 polymerase inhibitor 57 Infected Patients 57 mg q#h 57 relapsed SCLC 57 rFVIIa 57 Haptoglobin 57 relapsed ovarian cancer 57 entecavir 57 zidovudine lamivudine 57 Hepsera adefovir dipivoxil 57 albumin excretion rate 57 detectable HCV RNA 57 T1a 57 IV metastatic melanoma 57 virus HCV protease inhibitor 57 hemagglutination inhibition 57 endophthalmitis 57 metastatic malignant 57 #mg BID [002] 57 tolterodine ER 57 TIMP 1 57 axitinib 57 humanized interleukin 6 57 SPRYCEL ® 57 #mg dose [002] 57 statistically significant p = 57 complete cytogenetic 57 serum urate 57 AZT zidovudine Retrovir 57 baseline LDH 57 thyroid carcinoma 57 gastric carcinoma 57 Subgroup analyzes 57 aged ≥ 57 C#Y 57 dose dose escalation 57 Toxicities 57 partial remissions 57 lymphocyte count 57 urothelial carcinoma 57 ano genital warts 57 HER2 overexpression 57 Ribavirin 57 Rapid Virologic Response 57 ribavirin Copegus ® 57 contralateral breast 57 viral load 57 satraplatin Phase 57 symptomatic BPH 57 μg kg 57 sUA 57 TRAIL receptor 57 infliximab 57 severe rotavirus gastroenteritis 57 TT genotype 57 isoenzyme 57 HBV vaccine 57 amrubicin 57 generation antisense inhibitor 57 azacitidine 57 log# IU mL 57 noninferior 57 fluticasone salmeterol 57 suppressive therapy 57 ABCB1 57 HT 2A 57 PegIntron 57 achieved CCyR 57 S. aureus infections 57 mcg QD 57 selective modulator 57 herpes zoster shingles 57 HGS ETR1 57 receiving INTRON 57 anthracyclines taxanes 57 T1c 57 neoplasias 57 elotuzumab 57 Serotype 57 Roche Pegasys 57 TORISEL 57 squamous histology 57 FluCAM 57 pimecrolimus cream 57 hematopoietic cancers 57 APPRAISE 57 prevalences 57 Subgroup analysis 57 refractory NSCLC 57 relapsers 57 cervical lesions 57 relapsed ALL 57 virologic breakthrough 57 thyroglobulin 57 budesonide foam 57 eosinophilic asthma 57 relapsed refractory 57 COPEGUS 57 Baseline characteristics 57 serogroup 57 HeFH 57 flutamide 57 terlipressin 57 TO AVOID PREGNANCY WHILE 57 cabazitaxel 57 IFN alfa 57 FDG uptake 57 weekly subcutaneous injections 57 Human Papillomavirus Quadrivalent Types 57 KRAS mutant tumors 57 Herpes Simplex Virus 57 atherogenic dyslipidemia 57 indolent NHL 57 vaccinees 57 patients coinfected 57 soluble tumor necrosis 57 metastatic CRC 57 Albuferon TM 57 sunitinib 57 postoperative chemotherapy 57 demyelinating 57 hypophosphatemia 57 glatiramer acetate 57 efalizumab 57 MOTIVATE 57 HIV1 57 β blockers 57 Supplementary Table 57 underwent surgical resection 57 pegylated interferons 57 PREZISTA r arm 57 urocortin 2 57 hypereosinophilic syndrome 57 baseline CD4 57 P = .# 57 Xanafide 57 Epratuzumab 57 cytologically confirmed 57 ceftriaxone 57 preoperative chemotherapy 57 univariate analysis 57 -#.# log# copies mL 57 chloride secretion 57 achieved ACR# 57 platelet reactivity 57 oral herpes 57 CHOP chemotherapy 57 S. aureus isolates 57 sunitinib Sutent ® 57 serum urate levels 57 postmenopausal osteoporotic women 57 Telbivudine 57 pegylated liposomal doxorubicin PLD 57 Allovectin 7 ® 57 Hematologic 57 Metastatic Colorectal Cancer 57 experienced virologic failure 57 NYHA Class II 57 DLTs 57 anterior uveitis 57 serum ALT 57 microsatellite instability 57 castrate resistant prostate cancer 57 Omacetaxine 57 lung metastases 57 grade cervical dysplasia 57 chlamydial infection 57 glufosfamide 57 MGUS 57 carcinoids 57 #mg ATC 57 docetaxel pretreated 57 fludarabine 57 moderately emetogenic 57 MYLOTARG 57 EBRT 57 cholangiocarcinoma 57 undetectable hepatitis C 57 IU mL 57 metastatic renal cell 57 chronic GVHD 57 serum creatinine levels 57 interferon therapy 57 distant metastasis 57 immune globulin intravenous 57 IFN gamma 57 anti CTLA 57 adverse reactions incidence 57 NNT = 57 neoplasm 57 Malignant Melanoma 57 antiviral activity 57 HCV infections 57 nucleoside naive 57 Peginterferon alfa 2b 57 tenofovir FTC 57 antithymocyte globulin 57 neurologic progression 57 PEG interferon 57 acute GvHD 57 immunodeficient 57 fasting triglyceride levels 57 HLA DR4 57 vertebral fracture 57 infliximab monotherapy 57 fulvestrant 57 relapsing remitting MS RRMS 57 CIMZIA TM certolizumab pegol 57 Lenalidomide 57 B7 H3 57 histologically proven 57 peg interferon 57 allogeneic SCT 57 median survivals 57 PEGylated Fab fragment 57 mg/m2/day 57 Plicera 57 salmeterol fluticasone 57 PSADT 57 unresectable tumors 57 prevalent vertebral fracture 57 sulfasalazine 57 VZV 57 conventional DMARDs 57 pmol L 57 SSc 57 MIC# [001] 57 plus MTX 57 multivariate analyzes 57 gefitinib Iressa 57 telbivudine 57 hepatic fibrosis 57 dose cytarabine 57 ACR# responses 57 IFN alpha 57 microscopic hematuria 57 viremic 57 cytarabine daunorubicin 57 CIMZIA ™ 57 eribulin mesylate 57 Glufosfamide 57 nondiabetic patients 57 potentially hepatotoxic 57 estramustine 57 venlafaxine XR 57 prucalopride 57 DMARDS 57 Her2/neu 56 Partial Response 56 cART 56 rFSH 56 estrogen receptor ER 56 Relapsed Refractory 56 promoter methylation 56 nonmelanoma skin cancers 56 squamous 56 BRCA2 mutation carriers 56 BRCA mutation carriers 56 Atypical Hemolytic Uremic Syndrome 56 sarcomatoid 56 ritonavir boosted lopinavir 56 NAbs 56 ALND 56 Castration Resistant Prostate Cancer 56 refractory chronic lymphocytic 56 NPH insulin 56 Hurthle cell 56 combination antiretroviral therapy 56 liver metastasis 56 Interferon alfa 56 acute myelogenous leukemia AML 56 remission CR 56 neutrophil count 56 mRNA expression 56 INVEGA ® 56 androgen independent 56 Complicated Skin 56 advanced NSCLC 56 LV dysfunction 56 paroxysmal AF 56 malignant neoplasm 56 EDSS scores 56 metastatic lesions 56 COPEGUS ribavirin 56 nucleoside analogue 56 NATRECOR ® 56 germline mutations 56 neoadjuvant treatment 56 undetectable viral loads 56 doxorubicin docetaxel 56 HCV RNA 56 serotype 56 oral vancomycin 56 ABCSG 56 dose regimens 56 EGFR mutation status 56 renal tumors